Redeye provides an update as we resume our coverage after CLS’ rights issue.
Ahead of Cibus' Q2 2024 report, we incorporate the acquisition of six properties, announced in late ...
Our earnings bridge: We expect Q2 Paper EBIT of PLN 38m, down from PLN 94m in Q1'24.
Q2 likely similar to Q1 Q2 seems to have developed in a similar way to Q1, with the trend of longer ...
What to expect in Q2'24 We expect sales of SEK 266m for Q2'24, implying a y-o-y decline of -11%, alo...
Redeye shares its preview of BONESUPPORT’s Q2 2024e results, due 11 July.
Duell publishes its business review for Q3 (March-May) on Wednesday 3rd of July.
Redeye briefly comments on Navigo announcing several leadership changes.
Last week Railcare announced a deal that will secure the supply of locomotives for some of its impor...
Redeye comments on the continued expansion into California with a new collaboration with United Heal...
Q2 report due Tuesday, 23 July – many moving parts Key factor looks to be possible imminent Medicare...
The Danish Systemic Risk Council recommends that the Faroe systemic risk buffer is hiked to 3% (curr...
Redeye comments on Optomed’s directed share issue, raising approximately EUR7.
Redeye comments on Medivir’s update from ESMO GI, showing improvements in fostrox’ TTP.
Yesterday evening, Hoylu communicated that a number of shareholders in the Company, including board ...
ODI Pharma announced on June 25th that the company has completed a first delivery of products to the...
Redeye provides its view on the recent financing of SEK80m and the 18-month OPTIMIZE-1 readout, a ph...
Redeye initiates coverage of CTEK, a market leader within premium low-voltage chargers that is lever...
Yesterday (25 June) we hosted a group presentation with Ferronordic.
We forecast 21% y-o-y ARR growth and 15% adj. EBITDA margin.
